Patent Board Urged In New Petition To Cancel UPenn T-Cell Technology
ALEXANDRIA, Va. — In a petition for inter partes review (IPR) filed April 12, a biopharmaceutical company and its subsidiary maintain a patent claiming an “anti-tumor effective amount” of chimeric antigen...To view the full article, register now.
Already a subscriber? Click here to view full article